FDA approves Novo nordisk Fiasp (Mendon Insulin Injection) 100u/mL label extension
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently announced that the U.SFood andDrug(http://Administration http://
(http:// has approved the Fiasp (Mendin insulin injection) 100u/mL label extensionFiasp is a quick-acting insulin that was approved by the FDA in 2017 to treat adult patients with diabetes with intravenous infusions or subcutaneous multiple injections (MDI) under the supervision ofMedical(http://professionalsFiasp is the first and only quick-acting insulin injection that does not have a pre-meal prescription, which is given before meals or within 20 minutes of starting the mealFiasp has a variety of dose options for multiple daily injections (MDI) and continuous subcutaneous insulin infusions:(1) 10mL small bottles for insulin pump or MDI;Fiasp is closer to the natural physiological insulin response after a meal without diabetics than conventional winter insulinTo date, Fiasp has been approved by the United States, the European Union, Canada, Australia, Switzerland and other markets for adult sesame and improved blood sugar control in adult patients with type 1 and type 2 diabetes
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
